Jean-Jacques Bienaim

2021

In 2021, Jean-Jacques Bienaim earned a total compensation of $18.3M as CEO at BioMarin Pharmaceutical, a 1% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$2,343,600
Option Awards$3,247,040
Salary$1,260,000
Stock Awards$11,342,306
Other$62,492
Total$18,255,438

Bienaim received $11.3M in stock awards, accounting for 62% of the total pay in 2021.

Bienaim also received $2.3M in non-equity incentive plan, $3.2M in option awards, $1.3M in salary and $62.5K in other compensation.

Rankings

In 2021, Jean-Jacques Bienaim's compensation ranked 384th out of 12,397 executives tracked by ExecPay. In other words, Bienaim earned more than 96.9% of executives.

ClassificationRankingPercentile
All
384
out of 12,397
97th
Division
Manufacturing
118
out of 5,492
98th
Major group
Chemicals And Allied Products
35
out of 2,367
99th
Industry group
Drugs
31
out of 2,090
99th
Industry
Pharmaceutical Preparations
17
out of 1,537
99th

Pay ratio

Jean-Jacques Bienaim's Pay$18,255,438
Median Employee's Pay$175,523
Pay Ratio

104

to 1

In 2021, the annual total compensation of Jean-Jacques Bienaim was $18,255,438.

The annual total compensation of the median employee at BioMarin Pharmaceutical was $175,523.

The ratio of Jean-Jacques Bienaim's pay to the pay of median employee was therefore 104 to one.

Source: SEC filing on April 12, 2022.

Bienaim's colleagues

We found four more compensation records of executives who worked with Jean-Jacques Bienaim at BioMarin Pharmaceutical in 2021.

2021

Henry Fuchs

BioMarin Pharmaceutical

President, Worldwide R&D

2021

C Guyer

BioMarin Pharmaceutical

Chief Technical Officer and Executive Vice President of Global Manufacturing and Technical Operations

2021

Jeff Ajer

BioMarin Pharmaceutical

Executive Vice President, Chief Commercial Officer

2021

Brian Mueller

BioMarin Pharmaceutical

Chief Financial Officer

News

You may also like